Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.43 |
| ▸ | JAK1 | P23458 | 6/20 | 0.43 |
| ▸ | TYK2 | P29597 | 6/20 | 0.43 |
| ▸ | FLT3 | P36888 | 5/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856023 | 1.00 | JAK2 (0.43) | JAK2JAK1TYK2FLT3GPR119 | |
| SCHEMBL29414232 | 0.78 | EIF2AK4 (0.46) | GPR119EIF2AK4 | |
| SCHEMBL22856021 | 0.78 | EIF2AK4 (0.46) | GPR119EIF2AK4 | |
| SCHEMBL29414167 | 0.75 | TYK2 (0.52) | JAK2JAK1TYK2FLT3JAK3 | |
| SCHEMBL22855941 | 0.75 | TYK2 (0.52) | JAK2JAK1TYK2FLT3JAK3 | |
| SCHEMBL22856034 | 0.75 | TYK2 (0.52) | JAK2JAK1TYK2FLT3JAK3 | |
| SCHEMBL24276489 | 0.74 | AURKA (0.53) | JAK2JAK1TYK2FLT3JAK3 | |
| SCHEMBL29414207 | 0.74 | AURKA (0.53) | JAK2JAK1TYK2FLT3JAK3 | |
| SCHEMBL30591930 | 0.74 | MAPT (0.54) | JAK2JAK1TYK2FLT3GPR119 | |
| SCHEMBL26107223 | 0.74 | MAPT (0.54) | JAK2JAK1TYK2FLT3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | GUANGZHOU INNOCARE PHARMA TECH CO. LTD. (CN) | 2025-10-21 | — | — | US | disclosed |
| EP-3990449-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | Guangzhou InnoCare Pharma Tech Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | JAK2 2/4885JAK1 3/4885TYK2 1/4885 |
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | JAK2 2/4885JAK1 3/4885TYK2 1/4885 |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | TYK2, JAK2, JAK1 | JAK2 2/4885JAK1 3/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.